Antenatal Body Shape Index and Pregnancy Complications

Relationship Between Antenatal Body Shape Index and Pregnancy Complications

Background/aim: Gestational diabetes (GDM), gestational hypertension (GHT) and preeclampsia are common complications of pregnancy. In this study, it was aimed to determine the relationship between body shape index (ABSI), calculated based on antenatal measurements of the height, weight and waist circumference, and GDM, GHT and preeclampsia.

Materials and methods: 170 patients at 6-16th weeks of gestation were prospectively analyzed. Body mass index (BMI) and ABSI were calculated. Patients were analyzed according to the presence of GDM, GHT and preeclampsia at follow-up.

Our study is the first in terms of its subject and makes a significant contribution to the literature.

Study Overview

• Status: Completed
• Conditions: Body Mass Index; Gestational Hypertension; Gestational Diabetes Mellitus (GDM); Waist Circumference; Preeclampsia (PE); Gestational Complications
• Intervention / Treatment: Other: The patients participating in the study were between 6 and 16 weeks of pregnancy. Height, body weight, and waist circumference were measured at the first antenatal visit at 2 weeks.

• Study Type: Observational
• Enrollment (Actual): 170

Contacts and Locations

Study Locations

• Turkey
  • Bolu, Turkey, 14030
    • Abant Izzet Baysal University Faculty of Medicine, 14030, Bolu, Turkey

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

170 patients at 6-16th weeks of gestation

Description

Inclusion Criteria:

• Having a singleton pregnancy
• Pregnancy follow-up and birth must have taken place at Bolu Abant İzzet Baysal University Training and Research Hospital.
• Voluntary informed consent form must be signed to participate in the study.

Exclusion Criteria:

• Multiple pregnancies
• Additional systemic and chronic diseases (chronic hypertension, DM, hepatic diseases such as cholestasis, cardiac diseases, rheumatic diseases, renal diseases…)
• History of Gestational Diabetes, Gestational Hypertension and Preeclampsia in previous pregnancies

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

184 pregnant women who applied to Bolu Abant İzzet Baysal Training and Research Hospital

Other: The patients participating in the study were between 6 and 16 weeks of pregnancy. Height, body weight, and waist circumference were measured at the first antenatal visit at 2 weeks.; 170 patients at 6-16th weeks of gestation were prospectively analyzed. Body mass index (BMI) and ABSI were calculated. Patients were analyzed according to the presence of GDM, GHT and preeclampsia at follow-up.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Calculation of body shape index at 6-16 weeks of gestation	The study included pregnant women who applied to the Obstetrics and Gynecology outpatient clinic of Bolu Abant İzzet Baysal Training and Research Hospital between September 2023 and March 2024. During the first antenatal examination of the patients at 6-16 weeks of pregnancy, body shape indexes were calculated by measuring height, body weight and waist circumference.	6-16 weeks of gestation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients developing pregnancy complications	Patients whose body shape index was calculated at 6-16 weeks of gestation were evaluated during pregnancy follow-up according to the development of Gestational Diabetes, Gestational Hypertension and Preeclampsia.	gestation period and first 6 weeks postpartum

Collaborators and Investigators

• Sponsor: Abant Izzet Baysal University

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2023
• Primary Completion (Actual): March 1, 2024
• Study Completion (Actual): April 1, 2024

Study Registration Dates

• First Submitted: May 23, 2025
• First Submitted That Met QC Criteria: June 12, 2025
• First Posted (Actual): June 15, 2025

Study Record Updates

• Last Update Posted (Actual): June 15, 2025
• Last Update Submitted That Met QC Criteria: June 12, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Keywords: gestational diabetes; preeclampsia; waist circumference; gestational hypertension; body shape index
• Additional Relevant MeSH Terms: Urogenital Diseases; Endocrine System Diseases; Vascular Diseases; Cardiovascular Diseases; Female Urogenital Diseases and Pregnancy Complications; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Diabetes, Gestational; Pre-Eclampsia; Hypertension, Pregnancy-Induced; Hypertension; Pregnancy Complications
• Other Study ID Numbers: AbantIBU-elifbetulesmer-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No